The EU’s drug regulator said in April that its own review had found no evidence that this class of drugs was linked to suicidal thoughts. | Photo: Shutterstock
Britain’s health regulator said Wednesday that available data do not establish a link between a popular class of diabetes and obesity drugs, including Novo Nordisk’s Wegovy, and suicidal thoughts.
The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data on the class of drugs, known as GLP-1 receptor agonists, more than a year ago after some patients reported thoughts of suicide or self-harm.
“We conclude that the available data do not support a causal association between GLP-1 receptor agonists and suicide, suicidal ideation, self-harm and depression and therefore no update to the product information is warranted at this time,” it said in a statement.
The UK review began weeks after the European Union took similar action. It covered Wegovy and another Novo Nordisk drug, Ozempic, which contains the active ingredient semaglutide and is approved to treat type 2 diabetes.
The EU’s drug regulator said in April that its own review had found no evidence that this class of drugs is linked to suicidal thoughts.
The U.S. Food and Drug Administration said in January that its preliminary review had found no evidence that GLP-1 drugs were linked to suicidal thoughts, but it would continue to study the issue.
(Only the headline and image of this report may have been reworked by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First published: September 4, 2024 | 22:45 IS
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.